Innate Pharma - ADR
IPHA
Get informed when a big investor buys or sells
+ FollowMarket Cap$165.27M
Close$
$-0.13
107.5% downside
Current Fair Value
107.5% downsideOvervalued by 107.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $165.27 Million |
|---|---|
| Enterprise Value | $162.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.89 |
| Outstanding Shares | 91,412,000 |
Return
| Return on Equity | 396.69% |
|---|---|
| Return on Assets | -137.27% |
| Return on Invested Capital | -355.17% |
Valuation & Multiples
| P/E Ratio | -2.9 |
|---|---|
| PEG | -24.57 |
| Price to Sales | - |
| Price to Book Ratio | -1.76 |
| Enterprise Value to Revenue | 13.09 |
| Enterprise Value to EBIT | -1.76 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -1.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$5.70 M
Average shareholder expectationNext Earnings Call
Expected Date
September 17, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$6.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.20%▼ 0.12% |
|---|---|
| Total Invested | $235,456▼ 51.30% |
| Investors Holding | 9▼ 2.00% |
ESG Score
No data
About Innate Pharma
244 employees
CEO: Mondher Mahjoubi